Holen Sie sich die Stockscreener-App
0.0021
90.45%
-0.0199
Schlusskurs vom Vortag:
$0.022
Offen:
$0.0021
24-Stunden-Volumen:
945
Relative Volume:
0.29
Marktkapitalisierung:
$N/A
Einnahmen:
$9.94M
Nettoeinkommen (Verlust:
$-97.82M
KGV:
-0.000684
EPS:
-3.07
Netto-Cashflow:
$-100.02M
1W Leistung:
-90.45%
1M Leistung:
-90.45%
6M Leistung:
-98.42%
1J Leistung:
-99.50%
1-Tages-Spanne:
$0.0015
$0.0021
1-Wochen-Bereich:
$0.0015
$0.0021
52-Wochen-Spanne:
$0.0015
$0.0282
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Firmenname
Syros Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie SYRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.0015 | 0 | 9.94M | -97.82M | -100.02M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
378.94 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.83 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.02 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
675.61 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
297.00 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-08 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2019-02-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-11-05 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-03-13 | Bestätigt | Wedbush | Outperform |
| 2017-10-31 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-23 | Eingeleitet | ROTH Capital | Neutral |
| 2017-08-10 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
Alle ansehen
Syros Pharmaceuticals Inc Aktie (SYRS) Neueste Nachrichten
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $3.33 - Defense World
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Levi & Korsinsky Reminds Syros Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities LawsSYRS - ACCESS Newswire
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Rating of “Hold” from Analysts - Defense World
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
SYRS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Syros Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - MSN
Rege Nephro Acquires Assets from Syros Pharmaceuticals (SYRS) - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS) | SYRS Stock News - GuruFocus
Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Phar - GuruFocus
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - digitalmore.co
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Brokerages - Defense World
Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday - Defense World
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India
Analyze Syros Pharmaceuticals Inc (NASDAQ: SYRS) Before Investing. - stocksregister.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Syros Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Syros Pharmaceuticals settles debt with Oxford Finance By Investing.com - Investing.com South Africa
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com India
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga
Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025 - Marketscreener.com
Syros Pharmaceuticals, Inc. Announces Management Changes -February 28, 2025 at 04:15 pm EST - Marketscreener.com
Finanzdaten der Syros Pharmaceuticals Inc-Aktie (SYRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
Kapitalisierung:
|
Volumen (24h):